Among the cancers that resist every standard weapon medicine offers, head and neck tumours have long represented a particular kind of despair — a narrowing corridor with no visible door. A clinical trial conducted across 55 hospitals in 11 countries has now reported that a bispecific antibody called amivantamab shrank tumours in 42% of patients who had exhausted chemotherapy and immunotherapy, eliminating disease entirely in 15 cases. The finding, emerging from London's Institute of Cancer Research, suggests that simultaneously blocking two cancer growth pathways while reawakening the immune s
Evening Standard
· May 30, 2026
· health
· 3 min de leitura
High
Apuração: Verificado
Cancer injection destroys resistant tumours in breakthrough trial
Patients with treatment-resistant head and neck cancer experienced significant symptom relief including reduced pain, swelling, and improved quality of life compared to chemotherapy side effects.
◉
Health & Medicine
8098 artigos relacionados
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 100% correspondência
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 99% correspondência
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% correspondência
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% correspondência
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% correspondência
Cobertura Relacionada
The Guardian · Aug 20
Hundreds of thousands await GCSE results as gender gap narrows to 10-year low
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Viés e Enquadramento
⚖
Article presents cancer treatment trial results with optimistic framing and expert endorsement, lacking critical perspective on limitations, side effects, or comparative efficacy data.
Bias Direction
center-right
Confidence
MED
Breakthrough narrative with emphasis on unprecedented success and expert validation. Uses patient testimonial to humanize positive outcomes. Minimizes discussion of trial limitations, sample size context, or long-term efficacy questions.
unprecedentedly strong responses
eradicated entire tumours
breakthrough trial
very striking
potential to benefit many thousands
Oncologists or researchers not involved in the trial offering independent assessment
Discussion of trial phase limitations (appears to be Phase 2, not Phase 3)
Comparative efficacy data against existing treatments
Detailed adverse event profile or long-term safety data
Cost/accessibility considerations for patients
Realistic timeline for drug approval and availability
Perspectives from patient advocacy groups on unmet needs
Impacto Geopolítico
🌎
Cancer treatment breakthrough has minimal geopolitical implications; primarily a medical advancement affecting healthcare access and pharmaceutical competition globally.
Escalation Risk
low
Confidence
HIGH
United Kingdom
European Union
United States
Global healthcare markets
Johnson & Johnson strengthens market position in oncology; UK's Institute of Cancer Research enhances scientific soft power; potential shift in treatment accessibility favoring developed nations with advanced healthcare infrastructure.
Lente Econômica
📈
Breakthrough cancer treatment amivantamab shows 42% tumor shrinkage in resistant cases, potentially creating significant pharmaceutical market opportunity and reducing healthcare costs through improved outcomes.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical devices
Hospital and clinical services
Health insurance and NHS budgets
Patients gain access to effective treatment option for previously untreatable cancers, reducing suffering and improving quality of life. Potential reduction in long-term healthcare costs and lost productivity from cancer treatment. Improved outcomes may increase demand for cancer screening and early detection services.
Likely accelerated regulatory approval pathways (NICE evaluation, FDA fast-track consideration). Potential NHS budget reallocation toward oncology. Pricing negotiations between Johnson & Johnson and healthcare systems. Possible expansion of cancer treatment access programs. May influence future R&D investment in immunotherapy combinations.